These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

93 related items for PubMed ID: 18658049

  • 1. Atheroprotective effect of human apolipoprotein A5 in a mouse model of mixed dyslipidemia.
    Mansouri RM, Baugé E, Gervois P, Fruchart-Najib J, Fiévet C, Staels B, Fruchart JC.
    Circ Res; 2008 Aug 29; 103(5):450-3. PubMed ID: 18658049
    [Abstract] [Full Text] [Related]

  • 2. Peroxisome proliferator-activated receptor-alpha gene level differently affects lipid metabolism and inflammation in apolipoprotein E2 knock-in mice.
    Lalloyer F, Wouters K, Baron M, Caron S, Vallez E, Vanhoutte J, Baugé E, Shiri-Sverdlov R, Hofker M, Staels B, Tailleux A.
    Arterioscler Thromb Vasc Biol; 2011 Jul 29; 31(7):1573-9. PubMed ID: 21474829
    [Abstract] [Full Text] [Related]

  • 3. Transcriptional regulation of apolipoprotein A5 gene expression by the nuclear receptor RORalpha.
    Genoux A, Dehondt H, Helleboid-Chapman A, Duhem C, Hum DW, Martin G, Pennacchio LA, Staels B, Fruchart-Najib J, Fruchart JC.
    Arterioscler Thromb Vasc Biol; 2005 Jun 29; 25(6):1186-92. PubMed ID: 15790933
    [Abstract] [Full Text] [Related]

  • 4. Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor alpha activators.
    Vu-Dac N, Gervois P, Jakel H, Nowak M, Bauge E, Dehondt H, Staels B, Pennacchio LA, Rubin EM, Fruchart-Najib J, Fruchart JC.
    J Biol Chem; 2003 May 16; 278(20):17982-5. PubMed ID: 12637506
    [Abstract] [Full Text] [Related]

  • 5. Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5.
    Fruchart-Najib J, Baugé E, Niculescu LS, Pham T, Thomas B, Rommens C, Majd Z, Brewer B, Pennacchio LA, Fruchart JC.
    Biochem Biophys Res Commun; 2004 Jun 25; 319(2):397-404. PubMed ID: 15178420
    [Abstract] [Full Text] [Related]

  • 6. The RXR agonist bexarotene improves cholesterol homeostasis and inhibits atherosclerosis progression in a mouse model of mixed dyslipidemia.
    Lalloyer F, Fiévet C, Lestavel S, Torpier G, van der Veen J, Touche V, Bultel S, Yous S, Kuipers F, Paumelle R, Fruchart JC, Staels B, Tailleux A.
    Arterioscler Thromb Vasc Biol; 2006 Dec 25; 26(12):2731-7. PubMed ID: 17008586
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia.
    Evans MJ, Mahaney PE, Borges-Marcucci L, Lai K, Wang S, Krueger JA, Gardell SJ, Huard C, Martinez R, Vlasuk GP, Harnish DC.
    Am J Physiol Gastrointest Liver Physiol; 2009 Mar 25; 296(3):G543-52. PubMed ID: 19136377
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants: the GOLDN study.
    Lai CQ, Arnett DK, Corella D, Straka RJ, Tsai MY, Peacock JM, Adiconis X, Parnell LD, Hixson JE, Province MA, Ordovas JM.
    Arterioscler Thromb Vasc Biol; 2007 Jun 25; 27(6):1417-25. PubMed ID: 17431185
    [Abstract] [Full Text] [Related]

  • 13. Apolipoprotein A5 and triglyceridemia. Focus on the effects of the common variants.
    Hubacek JA.
    Clin Chem Lab Med; 2005 Jun 25; 43(9):897-902. PubMed ID: 16176166
    [Abstract] [Full Text] [Related]

  • 14. Differential regulation of the human versus the mouse apolipoprotein AV gene by PPARalpha. Implications for the study of pharmaceutical modifiers of hypertriglyceridemia in mice.
    Prieur X, Lesnik P, Moreau M, Rodríguez JC, Doucet C, Chapman MJ, Huby T.
    Biochim Biophys Acta; 2009 Aug 25; 1791(8):764-71. PubMed ID: 19362162
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Analysis of apolipoprotein A5, c3, and plasma triglyceride concentrations in genetically engineered mice.
    Baroukh N, Bauge E, Akiyama J, Chang J, Afzal V, Fruchart JC, Rubin EM, Fruchart-Najib J, Pennacchio LA.
    Arterioscler Thromb Vasc Biol; 2004 Jul 25; 24(7):1297-302. PubMed ID: 15117734
    [Abstract] [Full Text] [Related]

  • 17. Gender-modulated impact of apolipoprotein A5 gene (APOA5) -1131T>C and c.56C>G polymorphisms on lipids, dyslipidemia and metabolic syndrome in Turkish adults.
    Komurcu-Bayrak E, Onat A, Poda M, Humphries SE, Palmen J, Guclu F, Can G, Erginel-Unaltuna N.
    Clin Chem Lab Med; 2008 Jul 25; 46(6):778-84. PubMed ID: 18601598
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Is apolipoprotein A5 a novel regulator of triglyceride-rich lipoproteins?
    Jakel H, Nowak M, Helleboid-Chapman A, Fruchart-Najib J, Fruchart JC.
    Ann Med; 2006 Jul 25; 38(1):2-10. PubMed ID: 16448983
    [Abstract] [Full Text] [Related]

  • 20. In vivo characterization of human APOA5 haplotypes.
    Ahituv N, Akiyama J, Chapman-Helleboid A, Fruchart J, Pennacchio LA.
    Genomics; 2007 Dec 25; 90(6):674-9. PubMed ID: 17936576
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.